Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
4basebio UK Societas ( (GB:4BB) ) has issued an announcement.
4basebio PLC has signed a clinical supply agreement with a leading cancer immunotherapy developer to provide GMP-grade synthetic opDNA starting material for a Phase II trial. The deal underscores the company’s role as a key supplier of critical DNA inputs for advanced therapies, leveraging its enzymatic, cell-free manufacturing technology to support next-generation immunotherapies.
The agreement is expected to generate a seven-figure revenue stream over the next 12 months, signalling growing commercial momentum for 4basebio’s platform as a cost-effective replacement for plasmid DNA. By helping the client eliminate microbial contamination and antibiotic resistance genes, the partnership is intended to improve product safety and shorten development timelines, reinforcing 4basebio’s competitive positioning in the genetic medicines supply chain.
The most recent analyst rating on (GB:4BB) stock is a Buy with a £1600.00 price target. To see the full list of analyst forecasts on 4basebio UK Societas stock, see the GB:4BB Stock Forecast page.
Spark’s Take on 4BB Stock
According to Spark, TipRanks’ AI Analyst, 4BB is a Neutral.
The overall stock score is primarily impacted by the company’s challenging financial performance and bearish technical indicators. The negative valuation metrics further weigh down the score. While the CEO’s share purchase is a positive sign, it does not significantly offset the financial and technical weaknesses.
To see Spark’s full report on 4BB stock, click here.
More about 4basebio UK Societas
4basebio PLC is a Cambridge-based biotechnology company specialising in enzymatically produced synthetic DNA and mRNA for next-generation genetic medicines and vaccines. Its proprietary cell-free platform delivers GMP-grade DNA with high purity and scalability, targeting applications in gene therapy, genome editing, mRNA production and DNA vaccines, where it positions itself as a safer, faster alternative to plasmid-based systems.
The company focuses on providing application-specific DNA constructs that help partners accelerate proof-of-concept work and progression into clinical trials. By eliminating microbial contaminants and antibiotic resistance genes from its products, 4basebio aims to meet stringent safety and quality standards, strengthening its role as an enabling supplier across the genetic medicine ecosystem.
Average Trading Volume: 1,419
Technical Sentiment Signal: Sell
Current Market Cap: £67.36M
Find detailed analytics on 4BB stock on TipRanks’ Stock Analysis page.